EMA Wellness Partners with Mira Analytics for AI Endpoint Validation in Clinical Trials

EMA Wellness has entered into an exclusive partnership with Mira Analytics to deploy AI models for endpoint validation and rater surveillance across global central nervous system clinical trials, announced in a press release.

The integration will bring Mira’s AI models into EMAW’s clinical trial data platform, which standardizes multimodal data including eCOA, audio, video, and sensor inputs within a unified architecture. The combined system enables continuous monitoring of clinical interview data, identifying inconsistencies and improving rater reliability in real time.

EMA Wellness’ platform provides real time analytics and signal detection across multiple data types, supporting study design, participant selection, and endpoint reliability. The company’s GIANT platform is validated for use in Phase 2 and Phase 3 trials and is compliant with major data protection and regulatory standards.

Mira Analytics contributes AI models trained on thousands of recorded clinical interviews from global trials. These models automatically flag discrepancies between primary ratings and AI-generated scores, allowing sponsors to address quality issues during the course of a study. The partnership aims to enhance data consistency, reduce manual review effort, and improve the accuracy of clinical assessments at scale.